Persistence Market Research has announced the addition of the “Musculoskeletal Medicine Market: Global Industry Trend Analysis 2013 to 2017 and Forecast 2018 - 2026" report to their offering.

New York, NY -- (SBWire) -- 06/29/2018 --Musculoskeletal medicine incorporates spinal column and musculoskeletal disorders associated with sports, occupational injuries and age-related dysfunction. Musculoskeletal medicine is the diagnosis and management of all acute and chronic conditions affecting musculoskeletal system, i.e., muscles, bones, tendons, joints and ligaments and treatment of non-surgical lesions of the musculoskeletal system. Conditions diagnosed by a musculoskeletal expert include soft tissues and muscular injuries, joint injuries, bone disorders, and arthritis and simple or complex pain conditions.

Treatment other than medication may include acupuncture, physiotherapy, chiropractic care, therapeutic massage, structured rehabilitation programs and muscle stretching exercise. Musculoskeletal disorders are common problems distressing the senior population. A better understanding of musculoskeletal diseases may lead to the accomplishment of effective preventive measures, thus reducing public healthcare expenditure and improving the quality of life in the geriatric population. Technological advancements in orthopedic devices with increasing awareness among people may set for unprecedented demand for physical and occupational therapies and medicines and increase opportunities for healthcare suppliers and providers.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/22906

Increasing Prevalence of Chronic Musculoskeletal Disorder

The World Health Organization estimated that musculoskeletal diseases are the fifth large cause of deaths due to disability. Globally, one in four people report chronic musculoskeletal damages in both developed and developing countries. Musculoskeletal conditions are accountable for a major health problem in the Australian health system, affecting around 31% of the inhabitants, more than 6 million Australians. These conditions consume massive healthcare resources, representing almost 25% of the total cost of illness in the western countries. Musculoskeletal conditions are the most common reason of physical disability with severe long-term pain.

Back pain, joint disorders, osteoarthritis, rheumatoid arthritis and osteoporosis contribute to musculoskeletal diseases, and it has been targeted as a national health priority area with a national action plan by the Department of Health and Ageing. Also, nowadays people are willing to devote time and money to educate themselves about treatment possibilities and generate a personalized care way that will assist them to reduce pain and sustain an active lifestyle.

Factors Driving and Restraining the Musculoskeletal Medicine Market

The global musculoskeletal medicine market is majorly driven by the rise in geriatric population and also by increase in number of orthopedic physicians specialized in sports medicine, joint, hand and spine replacement. Increasing awareness among people regarding the disease and its treatment options and willingness to live longer are also factors contributing to the growth of the market. Similarly, providing advanced academic training to the healthcare professionals of musculoskeletal disorders, such as medical doctors, nurses, occupational therapists, physiotherapists and other allied healthcare professionals, community practitioners and researchers is expected to boost the demand for musculoskeletal medicine and therapies in the global market. Increasing prevalence of bone disorders and joint-related injuries is another factor driving the demand for musculoskeletal medicines across the globe.

However, the use of heavy-duty drugs in treating musculoskeletal pain is both inadequate and contradictory, strong data is needed to support clinical practice, which restricts the growth of the musculoskeletal medicine market in various regions.

Increasing Acceptance of Muscle Relaxants

Major portion of the market has been covered by muscle relaxants and analgesics segments, which include non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Analgesic are prescribed mostly in primary care when treating patients with a musculoskeletal condition. The prescribing pattern of analgesics may follow the WHO analgesic ladder of prescription as there is a limited use of strong analgesics at first session. However, additional research into the field of musculoskeletal pain is required to determine if these patterns of prescribing represent the optimal management ways while managing musculoskeletal conditions.

Musculoskeletal Medicine by Route of Administration

The doctors prescribe drugs along with topical therapy. The method of treating pain with topical therapy is disappearing and the prominence is on opioids, NSAIDs and acetaminophen. If the condition is cannot be controlled by drugs and topical agents, the physicians recommend for injection therapy.

Increasing Demand for Musculoskeletal Therapies and Medicines

Hospital pharmacies and retail pharmacies segments both pose strong position in the market due to increase in demand for musculoskeletal therapies and treatment. These distribution channels contribute significant portion of revenue share in the overall market. Further, the growing trend of routine examination would flourish the growth of musculoskeletal medicine globally.

Regional Market Outlook

North America will continue to dominate the global market due to availability of more number of hospitals and clinics. Europe is expected to hold second largest market share in global musculoskeletal medicine market due to growing awareness among individuals for chronic diseases.

Request Report for TOC @ https://www.persistencemarketresearch.com/toc/22906

Competition Outlook

Examples of some of the key players identified in the global musculoskeletal medicine market are as follows:

Small-Scale Manufacturers/Providers

Medium-Scale Manufacturers/Providers

Large-Scale Manufacturers/Providers

Actavis Elizabeth
Martec USA LLC
Acorda Therapeutics
Apotex Inc.
CorePharma, LLC
Sawai Pharmaceutical Co., Ltd
Endo International plc
Hikma Pharmaceuticals
Fresenius Kabi AG
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Novartis Pharmaceuticals Corp
Hoffmann la Roche Inc
Hospira Inc
Valeant Pharmaceuticals International, Inc
Dr. Reddy's Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.